A new study published in the journal of Contact Lens & Anterior Eye showed that the risk of keratoconus and corneal erosion is considerably higher in individuals with allergic ...

Madurai: The ophthalmology department at Government Rajaji Hospital (GRH) has performed 22 advanced corneal procedures in the past six months, offerin.

Glaukos (NYSE:GKOS) reported record fourth-quarter and full-year 2025 results and reaffirmed its 2026 revenue outlook, with management pointing to continued momentum in iDose TR for glaucoma and the ...

Analysts expect Glaukos to report a loss of 21 cents per share on revenue of $130.37 million for the fourth quarter, representing year-over-year revenue growth of 23.6% despite a narrowing loss. The ...

Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript February 17, 2026 Glaukos Corporation misses on earnings ...

The company reaffirmed its 2026 net sales guidance range of $600 million to $620 million, driven by iDose TR in the U.S. glaucoma segment and the launch of Epioxa in corneal health. Gilliam detailed, ...

On February 17, 2026, Glaukos reported record fourth-quarter 2025 net sales of $143.1 million, up 36% year over year, driven by a 42% surge in glaucoma revenue and 53% growth in U.S. glaucoma sales, ...

"I had an MRSA infection caused by a C-section. They had to cut open my stitches and pack my wound with gauze. The gauze needed to be replaced, and the wound had to be cleaned twice a day. It was ...

Epi-off ACXL improves the ocular surface and stabilizes ectasia progression in pediatric patients with keratoconus, a study shows.

Glaukos Corporation GKOS reported fourth-quarter 2025 adjusted loss of 28 cents per share, which missed the Zacks Consensus ...

Allergic conjunctivitis was linked to a significantly increased risk for keratoconus in a large real-world study published in ...

The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens ...